Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.
Saved in:
| Title: | Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. |
|---|---|
| Authors: | Monberg TJ; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Kudling T; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Albieri B; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Ellebaek E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Donia M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Eefsen RL; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., von Buchwald C; Department of ORL, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Denmark., Kistler C; TILT Biotherapeutics Ltd, Helsinki., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki., Clubb J; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki., Westergaard MCW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. |
| Source: | Immuno-oncology technology [Immunooncol Technol] 2024 Aug 12; Vol. 24, pp. 100726. Date of Electronic Publication: 2024 Aug 12 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918281581106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0188 (Electronic) Linking ISSN: 25900188 NLM ISO Abbreviation: Immunooncol Technol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39801682 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Monberg+TJ%22">Monberg TJ</searchLink>; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22Kudling+T%22">Kudling T</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Albieri+B%22">Albieri B</searchLink>; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22Pakola+S%22">Pakola S</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Ellebaek+E%22">Ellebaek E</searchLink>; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22Donia+M%22">Donia M</searchLink>; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22Eefsen+RL%22">Eefsen RL</searchLink>; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22von+Buchwald+C%22">von Buchwald C</searchLink>; Department of ORL, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Denmark.<br /><searchLink fieldCode="AU" term="%22Kistler+C%22">Kistler C</searchLink>; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Santos+JM%22">Santos JM</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Clubb+J%22">Clubb J</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Haybout+L%22">Haybout L</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Westergaard+MCW%22">Westergaard MCW</searchLink>; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22Quixabeira+DCA%22">Quixabeira DCA</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Jirovec+E%22">Jirovec E</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Havunen+R%22">Havunen R</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Sorsa+S%22">Sorsa S</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Cervera-Carrascon+V%22">Cervera-Carrascon V</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.<br /><searchLink fieldCode="AU" term="%22Hemminki+A%22">Hemminki A</searchLink>; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Svane+IM%22">Svane IM</searchLink>; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229918281581106676%22">Immuno-oncology technology</searchLink> [Immunooncol Technol] 2024 Aug 12; Vol. 24, pp. 100726. <i>Date of Electronic Publication: </i>2024 Aug 12 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9918281581106676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2590-0188 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225900188%22">25900188 </searchLink><i>NLM ISO Abbreviation: </i>Immunooncol Technol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39801682 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.iotech.2024.100726 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 100726 Titles: – TitleFull: Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Monberg TJ – PersonEntity: Name: NameFull: Kudling T – PersonEntity: Name: NameFull: Albieri B – PersonEntity: Name: NameFull: Pakola S – PersonEntity: Name: NameFull: Ellebaek E – PersonEntity: Name: NameFull: Donia M – PersonEntity: Name: NameFull: Eefsen RL – PersonEntity: Name: NameFull: von Buchwald C – PersonEntity: Name: NameFull: Kistler C – PersonEntity: Name: NameFull: Santos JM – PersonEntity: Name: NameFull: Clubb J – PersonEntity: Name: NameFull: Haybout L – PersonEntity: Name: NameFull: Westergaard MCW – PersonEntity: Name: NameFull: Quixabeira DCA – PersonEntity: Name: NameFull: Jirovec E – PersonEntity: Name: NameFull: Havunen R – PersonEntity: Name: NameFull: Sorsa S – PersonEntity: Name: NameFull: Cervera-Carrascon V – PersonEntity: Name: NameFull: Hemminki A – PersonEntity: Name: NameFull: Svane IM IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 08 Text: 2024 Aug 12 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2590-0188 Numbering: – Type: volume Value: 24 Titles: – TitleFull: Immuno-oncology technology Type: main |
| ResultId | 1 |
